Racura Oncology Valuation Multiples

Racura Oncology Overview

About Racura Oncology

Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.

Founded

2011

HQ

Employees

N/A

Website

racuraoncology.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: $868K

EBITDA: ($4M)

EV

$287M

Valuation Multiples

Multiples.vc

Start free trial

Racura Oncology Financials

Racura Oncology reported last 12-month revenue of $868K and negative EBITDA of ($4M).

In the same LTM period, Racura Oncology generated ($4M) in EBITDA losses and had net loss of ($4M).

Racura Oncology P&L

In the most recent fiscal year, Racura Oncology reported revenue of — and net income of —.

Racura Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX

Racura Oncology Stock Performance

Racura Oncology has current market cap of $302M, and enterprise value of $287M.

Racura Oncology's stock price is $1.66.

Racura Oncology Valuation Multiples

Racura Oncology trades at 330.7x EV/Revenue multiple, and (66.5x) EV/EBITDA.

Racura Oncology Financial Valuation Multiples

As of March 29, 2026, Racura Oncology has market cap of $302M and EV of $287M.

Equity research analysts estimate Racura Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Racura Oncology has a P/E ratio of (69.6x).

Racura Oncology Margins & Growth Rates

Racura Oncology's revenue in the last 12 month declined by (100%).

Racura Oncology's rule of 40 is (597%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Racura Oncology's rule of X is (747%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Racura Oncology Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Racura Oncology M&A Activity

Racura Oncology acquired XXX companies to date.

Last acquisition by Racura Oncology was on XXXXXXXX, XXXXX. Racura Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Racura Oncology Investment Activity

Racura Oncology invested in XXX companies to date.

Racura Oncology made its latest investment on XXXXXXXX, XXXXX. Racura Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).